Catalina Capital Group LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Catalina Capital Group LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,593 shares of the company’s stock, valued at approximately $82,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TNGX. Barclays PLC grew its holdings in Tango Therapeutics by 78.3% in the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after buying an additional 55,470 shares during the period. Geode Capital Management LLC grew its holdings in Tango Therapeutics by 11.6% in the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after purchasing an additional 142,710 shares during the period. XTX Topco Ltd increased its position in Tango Therapeutics by 340.1% during the third quarter. XTX Topco Ltd now owns 44,191 shares of the company’s stock worth $340,000 after purchasing an additional 34,150 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in Tango Therapeutics during the third quarter worth approximately $385,000. Finally, State Street Corp boosted its holdings in shares of Tango Therapeutics by 26.8% in the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after purchasing an additional 489,949 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, Director Mace Rothenberg purchased 10,000 shares of Tango Therapeutics stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $3.78 per share, with a total value of $37,800.00. Following the completion of the acquisition, the director now owns 31,250 shares of the company’s stock, valued at approximately $118,125. This trade represents a 47.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on TNGX. Guggenheim cut their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. B. Riley decreased their target price on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research report on Friday, November 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.14.

Tango Therapeutics Stock Up 4.5 %

Shares of NASDAQ:TNGX opened at $3.04 on Wednesday. The company has a market capitalization of $326.56 million, a price-to-earnings ratio of -2.58 and a beta of 0.80. The company has a 50 day moving average of $3.17 and a two-hundred day moving average of $6.19. Tango Therapeutics, Inc. has a 52-week low of $2.59 and a 52-week high of $12.89.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.